News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Vascular Closure Systems, Inc. Announces 30-Day Follow-Up Results for Phase I of the First in Human (FIH) Clinical Use, of the FastSeal® Bioabsorbable Vascular Access Closure System


6/29/2012 9:45:00 AM

PALO ALTO, Calif.--(BUSINESS WIRE)--Vascular Closure Systems, Inc.:

30-Day Follow-Up Results of the First in Human (FIH) Clinical Test Series of the FastSeal® Bioabsorbable Vascular Access Closure System – 100% Success Rate, Including Patients with Challenging Anatomy and Vessel Condition.

The company is pleased to announce that the 30-Day follow-up results for the Phase I FIH clinicals have been perfect, as confirmed by doppler and ultrasound evaluation. The evaluation confirmed normal vessel healing, with complete absorption of the FastSeal® sealing element. During the follow-up, no adverse events were observed - no hematoma, pseudoaneurysm or fistulas were present in any of the patients. All patients were asymptomatic and the comfort of the device was excellent, with no groin pain during the deployment, immediately after, at 7, and 30-days after the procedure.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES